DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

TFX·Teleflex Incorporated

$.
+. (+.%)
After Hours
High
$137.09
Open
$135.57
Market Cap
6.02B
52W High
$139.67
Low
$134.31
P. Close
$135.68
P/E
-
52W Low
$100.18
Fwd P/E
12.83
DailyIQ Est.
$147.67
Technical Score (1D)
95
BUY
News Sentiment
55
BULLISH
BMO Capital has just launched coverage of Teleflex (TFX), issuing an Outperform rating and a $159 price target, a move that signals fresh analyst confidence in the company’s growth trajectory. The rating hinges on Teleflex’s diversified product portfolio and its strong market positioning, which analysts believe will support continued revenue expansion through innovation and strategic acquisitions. Because the coverage is new, the announcement is likely to lift trading volume and attract additional investor attention, potentially tightening the bid‑ask spread. The rating also raises expectations for TFX’s upcoming earnings guidance, as investors will now be looking for the company to confirm its projected upside. In the next 1–10 trading days, the market will be watching how TFX’s earnings report aligns with the $159 target and whether the company can deliver on its growth narrative. Analysts will also scrutinize competitive dynamics in the medical device space, particularly any pricing pressure or new entrants that could erode Teleflex’s market share. Additionally, any announcements of new acquisitions or product launches will be key to validating the Outperform thesis. Traders should monitor TFX’s earnings release for guidance revisions, as a downgrade or upside surprise could quickly alter the stock’s trajectory. Finally, keep an eye on broader market sentiment toward the healthcare sector, as shifts in risk appetite could influence how quickly the new coverage translates into price action.
Earnings Summary
Teleflex Incorporated is a global medical device manufacturer that specializes in single‑use products across vascular access, interventional, anesthesia, surgical, urology, and respiratory applications, positioning it within the broader medical instruments and supplies sector. In the most recent two quarters, Teleflex reported a decline in both revenue and earnings per share, with Q4 2025 revenue falling to $568.98 million and EPS to $1.93 versus Q2 2025 revenue of $780.89 million and EPS of $3.73; the Q1 2026 figures continued this downward trend with revenue of $548.26 million and EPS of $1.39, compared to Q3 2025 revenue of $892.90 million and EPS of $3.67. Despite the recent downturn, Teleflex has historically beaten analyst estimates in five of the six quarters examined, with the sole miss occurring in Q4 2025 when EPS fell short of the $3.77 estimate; revenue has shown a mixed trajectory, rising in Q2 and Q3 2025 before declining in the subsequent quarters. Recent coverage by BMO Capital and Argus Research has introduced fresh analyst optimism, with an Outperform rating and a $159 price target, while the company’s initiation of patient enrollment in the BIOMAG‑III study of its Freesolve magnesium scaffold has added a potential catalyst that could influence future valuation; elevated options activity and implied volatility further underscore market anticipation of forthcoming data. Investors should watch for the Q2 2026 earnings release, paying particular attention to guidance on revenue, EPS, and raw‑material cost management, as well as the first safety and efficacy data from the BIOMAG‑III study, which could materially affect Teleflex’s competitive positioning and margin outlook.

EPS

EstBeatMiss
$0.84$1.67$2.50$3.33$4.15Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.27 - -
Q1'26$1.22$1.39+13.6%
Q4'25$3.77$1.93-48.8%
Q3'25$3.38$3.67+8.6%
Q2'25$3.37$3.73+10.8%
Q1'25$2.88$2.91+0.9%

Revenue

EstBeatMiss
$480M$607M$734M$860M$987MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$565M - -
Q1'26$539M$548M+1.8%
Q4'25$928M$569M-38.7%
Q3'25 - $893M -
Q2'25 - $781M -
Q1'25 - $701M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TFX Stock Snapshot

TFX is currently trading at $135.73, giving Teleflex Incorporated a market cap of 6.02B. Today's range spans $134.31–$137.09, with shares opening at $135.57 and moving up $0.05 (0.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 55/100.

Over the past year TFX has traded between $100.18 and $139.67 - the current price is +35.5% off the 52-week low and -2.8% from the high. 19 analysts cover the stock with a Hold consensus and a mean 12-month target of $147.20 (range $135.00–$160.00), implying upside of +8.5%.

At 6.02B in Healthcare market cap, TFX isn't on every institutional screen - yet. The current setup (BUY, 95/100, neutral sentiment at 55/100, price $135.73 (near 52-week highs)) is the kind of data profile that changes that. When small-cap Healthcare names show bullish technicals with aligned news sentiment, discovery buying and fundamental upgrades can accelerate the move beyond what the signal alone predicts. Range: $100.18–$139.67.

News sentiment (55/100, neutral) plays a larger role in small-cap price discovery than in mega-cap names, because the analyst coverage base is narrower and each incremental news item carries more weight in the information set. For TFX — 6.02B in Healthcare market cap, technical score 95/100 (BUY), price $135.73 (near 52-week highs) — a sustained improvement in the news backdrop could accelerate the bullish technical thesis toward the upper end of the $100.18–$139.67 range faster than fundamental models would suggest.